S-amlodipine + nebivolol

Full Generic Medicine Info
Dosage/Direction for Use

Adult: 1 cap [S-Amlodipine 2.5mg + Nebivolol 5mg] once daily.
Allergic to dihydropyridine Ca antagonist, hypersensitivity to the active substance or to any of the excipients, liver insufficiency or liver function impairment. Pregnancy, lactation.
Special Precautions
History of allergies, psoriasis, hyperthyroidism, peripheral arterial disease, diabetes, elderly.
Adverse Reactions
Headache, fatigue, parasthesias and dizziness, insomnia, nausea, abdominal pain, flushing, pruritus, skin rash, dyspnea, weakness, muscular spasm, and dyspepsia.
S-amlodipine is an enantiomer of amlodipine, which blocks Ca ion outside the cardiac muscle cells and vascular smooth muscle cells via the Ca channel of cytomembrane. It directly dilates vascular smooth muscle, resisting hypertension. The mechanism of remitting angina pectoris is not yet determined completely. It can decrease myocardial ischemia through dilatation of the peripheral small artery, decreasing peripheral resistance, causing the reduction of energy consumption, and O2 requirement of cardiac muscle and dilating the coronary artery and coronary small artery at normal and ischemic areas, increasing the O2 supply of the cardiac muscle of the coronary spasm patients.
Nebivolol exerts its actions by exhibiting a high selectivity for beta-1 adrenergic receptors and also by reducing the peripheral vascular resistance by modulating NO release.
ATC Classification
C07AB12 - nebivolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on s-amlodipine + nebivolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in